Related Experiment Video
Updated: Jul 12, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Abstract:
Trials reported at the 2023 ESMO Congress showed significant improvements in median overall survival (OS)-for the first time ever-in patients newly diagnosed with advanced or metastatic urothelial carcinoma who received combination therapies instead of standard chemotherapy. In one trial, median OS nearly doubled in patients who received the antibody-drug conjugate enfortumab vedotin combined with the PD-1 inhibitor pembrolizumab compared with those who received standard chemotherapy-31.5 months versus 16.1 months. In a second trial, the combination of the PD-1 inhibitor nivolumab and standard chemotherapy bested standard chemotherapy alone.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Treatment Resistant Cancers
Endoscopic Studies II: Thoracocentesis
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Standards of Care II

